MedTrace Logo

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

NCT00145145 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-10-07

Study results available
· View outcomes & findings →

Summary

The purposes of this study are to determine whether immunization with the MAGE-3.A1 peptide mixed with CpG 7909 results in a detectable immune response; to determine the safety of this vaccine and to document the tumor response to the vaccine.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

MAGE-3.A1 peptide and CpG 7909

Sponsors & Collaborators

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Nicolas van Baren, MD · Ludwig Institute for Cancer Research

  • Thierry Boon, PhD · Ludwig Institute for Cancer Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-12
Primary Completion
2005-04-07
Completion
2008-04-28

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145145 on ClinicalTrials.gov